
- Volume 0 0
Hydase (hyaluronidase injection, USP)
PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit
Articles in this issue
about 20 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsabout 20 years ago
High Alert Insulin Binabout 20 years ago
Humira (adalimumab)about 20 years ago
INVANZ (ertapenem for injection)about 20 years ago
Compounding HOTLINEabout 20 years ago
Customer Guilty of Prescription Fraud by Supporting Friendabout 20 years ago
Counterfeit Drugs: A Life-or-Death Problemabout 20 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsabout 20 years ago
Can You Read These Rxs?about 20 years ago
What You Need to Know About Alzheimer's DiseaseNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.










































































































































































































